What Is BPC-157 and Why Does Dosing Matter?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide derived from a protein sequence found in human gastric juice, first described by researchers at the University of Zagreb. Its primary mechanism operates through nitric oxide synthase upregulation and downstream VEGF pathway activation, driving angiogenesis and tissue repair across a range of preclinical models including gastrointestinal, musculoskeletal, neurological, and systemic endpoints.
Dosing in research contexts matters for two distinct reasons. First, BPC-157 literature spans a wide range of administered doses — from 1 mcg/kg to over 1000 mcg/kg across different models — and the biological effects observed at lower doses are not always replicated at higher doses. Second, BPC-157 has three meaningfully different research routes (subcutaneous, oral, intraperitoneal) with different bioavailability, onset kinetics, and appropriate endpoints. Selecting the wrong route for a given research question undermines the validity of the model regardless of the dose used.
BPC-157 is sold by Evo Peptides for in vitro laboratory research only. Not for human or animal therapeutic use. All dosing values in this guide are drawn from published preclinical literature and are provided as research reference data, not clinical or therapeutic dosing recommendations.
Concentration Calculator — 5mg and 10mg Vials
The most common dosing error in peptide research is confusing syringe markings with injection volumes. A 1mL insulin syringe marked in 100 units means each "unit" = 0.01mL. When someone reads "10 units" they may mean 0.1mL — but the conversion depends entirely on the concentration. Calculate dose in mcg first, then back-calculate volume from concentration. Never work backwards from syringe markings without knowing the exact vial concentration.
Formula
Injection Volume (mL) = Target Dose (mcg) ÷ Vial Concentration (mcg/mL)
Example: Target 250mcg, vial concentration 2,500mcg/mL → 250 ÷ 2,500 = 0.1mL (= 10 units on a 100-unit insulin syringe)
Pre-Calculated Reference Cards
Every BPC-157 vial ships with a third-party HPLC and mass spec COA. BPC-157 5mg available in stock. Same-day shipping before 3:00 PM CST from Wisconsin.
Route Comparison: SubQ vs Oral vs IP
BPC-157 is one of the few research peptides for which all three major non-IV routes produce documented biological effects in preclinical models. The appropriate route depends entirely on the research endpoint — not on convenience. A systemic tissue repair study should not use oral administration; a GI mucosal model should not use subcutaneous injection.
Master Dosing Reference Table
The following table compiles dose ranges and protocol parameters from published BPC-157 preclinical literature. Values represent the ranges most commonly reported — they are not recommendations and should be interpreted in the context of specific study designs.
| Endpoint Category | Route | Dose Range (Rodent) | Frequency | Protocol Duration | Evidence Quality |
|---|---|---|---|---|---|
| Tendon / Ligament Repair | SubQ / IP | 1–10 mcg/kg/day | Daily | 2–4 weeks | Preclinical |
| Bone Healing | SubQ / IP | 10 mcg/kg/day | Daily | 4–8 weeks | Preclinical |
| Gastric Ulcer / GI Repair | Oral / IP | 10 mcg/kg (oral: up to 10 mg/kg) | Daily | 7–14 days | Preclinical |
| IBD / Colitis Models | Oral / IP | 10 mcg/kg–1 mg/kg | Daily | 2–4 weeks | Preclinical |
| Muscle Healing | SubQ / IP | 2–10 mcg/kg/day | Daily | 2–3 weeks | Preclinical |
| Neurological (Dopaminergic) | IP | 10 mcg/kg/day | Daily | 2–4 weeks | Limited |
| Cardiovascular (Cardiac) | SubQ / IP | 10 mcg/kg/day | Daily | 4 weeks | Limited |
| Wound Healing (Skin) | SubQ (systemic) or topical | 10 mcg/kg/day systemic | Daily | 7–14 days | Preclinical |
| NSAID Organ Protection | Oral / SubQ | 10 mcg/kg/day | Daily | Duration of NSAID exposure | Preclinical |
Protocol Design by Research Endpoint
Protocol design should match the dose, route, frequency, and duration to the specific biological endpoint being studied. The following summaries reflect the most replicated preclinical protocol designs from published literature.
Tissue Repair Protocols (Tendon, Bone, Muscle)
| Protocol Parameter | Recommended Design | Rationale |
|---|---|---|
| Route | SubQ or IP | Systemic delivery required for musculoskeletal endpoints |
| Dose | 10 mcg/kg/day | Most replicated dose in tissue repair literature |
| Frequency | Once daily | Consistent with 4–8h estimated t½; daily maintains exposure |
| Duration | 2–4 weeks for tendon; 4–8 weeks for bone | Endpoint-matched to biological healing timelines |
| Start point | Day 0 (injury day) or Day 1 post-injury | Most published protocols begin at or immediately after injury |
| Washout before collection | 24–48 hours (5× t½) | Allows plasma clearance before tissue collection |
Gastrointestinal / Gut Protocols
| Protocol Parameter | Recommended Design | Rationale |
|---|---|---|
| Route | Oral (gavage or drinking water) | GI mucosal endpoint requires local exposure; oral stability is validated |
| Dose | 10 mcg/kg (low) to 10 mg/kg (high) oral | Lower oral bioavailability requires substantially higher mass dose |
| Frequency | Once daily | Standard for oral rodent protocols |
| Duration | 7–14 days for acute models; 2–4 weeks for chronic IBD | Match to model progression timeline |
| Vehicle | Normal saline or water (0.9% NaCl) | Peptide stable in aqueous solution for same-day dosing |
Steady State & Measurement Timing
BPC-157's estimated 4–8 hour half-life means steady state is reached within ~2 days of daily dosing (4–5 half-lives). Begin collecting primary outcome measurements after steady state is established — not on Day 1 — unless the protocol is specifically studying acute single-dose effects. For tissue endpoints with longer biological timelines (tendon, bone), steady state timing is less critical than endpoint measurement timing.
Reconstitution Step-by-Step
BPC-157 is supplied lyophilized (freeze-dried) as a white or off-white powder. It must be reconstituted with bacteriostatic water (BAC water) before use. Do not use sterile water for multi-use vials — it lacks the benzyl alcohol preservative required for microbiological stability after the first withdrawal.
| Form | Temperature | Shelf Life | Notes |
|---|---|---|---|
| Lyophilized (sealed, unopened) | −20°C freezer | 24+ months | Stable long-term; keep dry and away from light |
| Lyophilized (opened, stored dry) | −20°C freezer | 12 months | Reseal tightly; minimize air/moisture exposure |
| Reconstituted (BAC water) | 2–8°C refrigerator | 28 days | Do not freeze; discard if cloudy or discolored |
| Reconstituted (sterile water) | 2–8°C refrigerator | 7 days | No preservative — single-use vial only |
Combining BPC-157 with TB-500 in Research
The BPC-157 + TB-500 combined protocol (the Wolverine Stack) is the most common multi-peptide design in preclinical tissue repair research. The scientific rationale is mechanistic complementarity: BPC-157 operates through the NO/VEGF pathway; TB-500 operates through G-actin sequestration and Thymosin Beta-4-mediated cell migration. They converge on angiogenesis and tissue repair through entirely different upstream pathways, making combined protocols scientifically valid for studying additive or synergistic effects.
- BPC-157: 10 mcg/kg/day SubQ or IP — reconstitute and administer separately
- TB-500: 2× weekly SubQ — different half-life (2–3 days) supports less frequent dosing
- Administration: Can be injected at the same or adjacent sites; no known incompatibility when reconstituted separately
- Duration: 2–4 weeks for most tissue repair endpoints; 4–8 weeks for bone models
- Source both from the same batch window to ensure COA methodology is consistent across both arms
Understanding the Evidence Quality
Most BPC-157 research is preclinical — animal models and in vitro studies. There is no published, formal human pharmacokinetic study with complete half-life determination, no Phase 1 dose-escalation trial, and no Phase 2/3 clinical data as of June 2026. The dose ranges in this guide reflect the most replicated values in preclinical literature. They should be understood as:
| Data Type | Evidence Level | What It Means |
|---|---|---|
| Dose ranges (1–10 mcg/kg) | Preclinical | Most replicated in rat/mouse models; not validated in humans |
| Half-life (4–8 hours) | Estimated | Derived from animal PK and detection window data; no formal human study |
| Oral stability | Preclinical | Multiple rodent studies confirm GI stability — stronger evidence base |
| Endpoint timelines | Preclinical | Based on histological and functional outcomes in animal models |
| TB-500 compatibility | Preclinical | Based on mechanistic rationale and combined protocol studies in rodent models |
BPC-157 is scheduled for PCAC advisory committee review on July 23, 2026, following its removal from FDA Category 2 on April 22, 2026. This process concerns compounding pharmacy access — it does not affect research-use-only (RUO) sales. BPC-157 remains available for laboratory research through RUO channels. See the BPC-157 FDA Status 2026 guide for full regulatory context.